Cancer Discov. 2020 Nov;10(11):OF2. doi: 10.1158/2159-8290.CD-ND2020-016. Epub 2020 Sep 18.
In the absence of specific therapeutic strategies for SARS-CoV-2, oncologists are exploring the potential of repurposing cancer drugs to treat COVID-19. For instance, androgen blockade with bicalutamide is being evaluated to tackle viral entry and replication, and it may be useful for patients with mild respiratory symptoms. Meanwhile, BTK inhibitors, such as acalabrutinib, could prove effective in mitigating severe, hyperinflammatory COVID-19.
在缺乏针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的特定治疗策略的情况下，肿瘤学家正在探索重新利用癌症药物治疗冠状病毒病（COVID-19）的潜力。例如，正在评估使用比卡鲁胺进行雄激素阻断以应对病毒进入和复制，这可能对有轻微呼吸道症状的患者有用。同时，布鲁顿酪氨酸激酶（BTK）抑制剂，如阿卡替尼，可能在减轻严重的、炎症反应过度的COVID-19方面证明有效。
